No insider purchase over the last 90 days. The latest, by Mahai Chris LaVictoire, was filed 20 Jul 2026.
Who traded when
BuySaleSince the insiders bought
- -14.1%Entry US$2.67 · Close at T+90 US$2.29
- +5.6%Entry US$22.15 · Close at T+90 US$23.39
- -8.1%Entry US$15.14 · Close at T+365 US$13.91
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended September 2025 · cache
- 527 shares@ US$19.920.0013% mcap100.0% of flowCommon StockSEC:0001104659-26-085027:0Canonical exit: 14 Oct 2026 (T+90)
- 7,923 shares@ US$16.8818100.0% of flowCommon StockSEC:0001104659-25-122394:0Canonical exit: 16 Mar 2026 (T+90)
- 41,623 shares@ US$14.142.9% of flowCommon StockSEC:0001510281-25-000498:1
- 6,989 shares@ US$14.100.8% of flowCommon StockSEC:0001510281-25-000498:0
- 40,208 shares@ US$14.072.8% of flowCommon StockSEC:0001510281-25-000492:1
- 24,328 shares@ US$13.992.7% of flowCommon StockSEC:0001510281-25-000492:0
- 2,026 shares@ US$13.990.1% of flowCommon StockSEC:0001510281-25-000488:1
- 700 shares@ US$14.130.1% of flowCommon StockSEC:0001510281-25-000488:0
- 15,116 shares@ US$14.281.7% of flowCommon StockSEC:0001510281-25-000481:0
- 14,083 shares@ US$14.041.6% of flowCommon StockSEC:0001510281-25-000449:0
- 23,723 shares@ US$13.892.6% of flowCommon StockSEC:0001510281-25-000436:0
- 400 shares@ US$13.830.0% of flowCommon StockSEC:0001510281-25-000435:0
- 10,710 shares@ US$14.071.2% of flowCommon StockSEC:0001510281-25-000428:0
- 11,419 shares@ US$12.711.2% of flowCommon StockSEC:0001510281-25-000325:0
- 23,729 shares@ US$12.082.4% of flowCommon StockSEC:0001510281-25-000315:0
- 600 shares@ US$12.040.0% of flowCommon StockSEC:0001510281-25-000308:1
- 730 shares@ US$12.280.1% of flowCommon StockSEC:0001510281-25-000308:0
- 12,689 shares@ US$11.981.3% of flowCommon StockSEC:0001510281-25-000291:0
- 1,366 shares@ US$12.190.1% of flowCommon StockSEC:0001510281-25-000287:0
- 9,144 shares@ US$11.780.9% of flowCommon StockSEC:0001510281-25-000226:0
- 1,700 shares@ US$11.920.2% of flowCommon StockSEC:0001510281-25-000219:0
- 15,400 shares@ US$11.671.5% of flowCommon StockSEC:0001510281-25-000211:0
- 30,156 shares@ US$11.142.8% of flowCommon StockSEC:0001510281-25-000204:0
- 6,889 shares@ US$11.570.4% of flowCommon StockSEC:0001510281-25-000186:1
- 10,321 shares@ US$12.231.1% of flowCommon StockSEC:0001510281-25-000186:0
25 of 113 declarations
About abrdn Life Sciences Investors
Saba Capital Management, L.P. accounts for 70 of the 88 filings at abrdn Life Sciences Investors: 31 purchases and 39 sales. Its three largest purchases date from April 2024: EUR 1,457,603 on April 26, EUR 1,181,297 on April 25 and EUR 982,928 on April 18. Its largest sales follow in 2025: EUR 581,547 on February 10, EUR 565,379 on March 31 and EUR 498,725 on September 22.
Overall, this fund, classed in the Finance & Banking sector and valued at USD 544.9 million, has 49 purchases worth EUR 11,086,227 (median EUR 113,789) and 39 sales worth EUR 7,101,522 (median EUR 135,434), or 56% purchases among open-market trades. Daniel R. Omstead (President) filed 7 times, all purchases, and Kathleen Goetz (Director) 3. Across the full history, 17 purchase filings are classed as clustered. A window of 2 filers runs from June 24 to July 16, 2024, worth EUR 196,758.
Read moreShow less
Activity is concentrated in 2024 (36 filings) and 2025 (40), against 1 to 5 a year in the other years. The 49 purchases have a 90-day result: median 9.5%, 80% positive (past stored results, not a forecast). Last twelve months: 2 filings, 2 purchases.
